NCT03806933 - Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

September 10, 2020

Study Completion Date

October 8, 2020

Conditions

Moderate to Severe Glabellar Frown Lines

Interventions

DRUG

NT 201

Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).

Trial Locations (9)

10707

Privatpraxis für Dermatologie und Ästhetische Medizin, Merz Investigational Site #0490306, Berlin

14467

Skin & Laser Center, Merz Investigational Site #0490362, Potsdam

20146

Universität Hamburg, Fachrichtung Kosmetik und Körperpflege, Merz Investigational Site #0490095, Hamburg

22609

Dermatologische Gemeinschaftspraxis Dr. Prager und Partner, Merz Investigational Site #0490345, Hamburg

37215

Tennessee Clinical Research Center, Merz Investigational Site #0010097, Nashville

91436

Clinical Testing of Beverly Hills, Merz Investigational Site #0010395, Encino

92121

Cosmetic Laser Dermatology, Merz Investigational Site #0010321, San Diego

92663

Medical Associates Inc., Merz Investigational Site #0010435, Newport Beach

94115

The Maas Clinics, Merz Investigational Site #0010338, San Francisco